Alnylam Pharmaceuticals (ALNY) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
18 Nov, 2026AMVUTTRA launch and commercial execution
After 18 months, launch growth was substantial, but demand pace remained below expectations; only one-third of targeted physicians had prescribed AMVUTTRA.
Prescribers reached 2,000 after a ~25% field-force expansion; priorities are both deeper engagement and broader physician adoption, converting engagement into patient starts.
HELIOS-B evidence, reported early-treatment outcomes, and quarterly subcutaneous dosing support the product proposition; 90% of patients can access treatment within 10 miles through infusion clinics.
Commercial strategy remains focused on execution; a search is underway for a leader to drive AMVUTTRA growth and potential future launches, with an appointment expected in the near future.
U.S. payer access
AMVUTTRA has coverage for 99% of U.S. lives, with first-line access for ~75%; ~50% of current patients use fee-for-service Medicare, while Medicare Advantage represents ~35%.
UnitedHealth and Aetna policies affect ~10% and ~5% of lives, respectively; for 2027, no additional major Medicare Advantage policy changes were anticipated, though plans review policies annually.
Differentiating AMVUTTRA’s clinical profile is the stated focus for maintaining first-line access; physicians may appeal step edits when they consider it the most appropriate treatment.
340B reimbursement changes
Effective Jan. 1, 2027, 340B reimbursement is changing from ASP +6% to ASP -28%; institutions purchase AMVUTTRA at WAC -23.1%.
Contracting and discounts are planned to keep 340B purchases viable; contracting is expected to be in place by mid-December and does not affect ASP.
Institutions may remain in 340B with contracting, shift to WAC purchasing, or use alternate infusion sites; WAC purchasing would be positive for pricing, while 340B discounts would pressure net price.
The impact depends on institutional purchasing choices; guidance is planned for mid-February after five to six weeks of experience under the new rule, including key 340B assumptions.
Latest events from Alnylam Pharmaceuticals
- TTR-led product growth lifted Q3 revenue 52%; a tax benefit boosted net income.ALNY
Q3 2026 - Brezosiran lowered CSF mHTT by up to 64%; a pivotal study is planned for 2027.ALNY
Investor update - AMVUTTRA’s strong growth and robust pipeline drive optimism for future expansion and innovation.ALNY
Morgan Stanley 24th Annual Global Healthcare Conference - Zilebesiran offers sustained BP control and CV risk reduction with twice-yearly dosing.ALNY
Investor update - Strong AMVUTTRA growth, reduced competition, and advancing pipeline drive optimism for future performance.ALNY
Wells Fargo 21st Annual Healthcare Conference - Deep TTR knockdown and early intervention drive clinical and commercial leadership in ATTR-CM.ALNY
ESC Congress Presentation - Q2 2026 revenues jumped 74% to $1.2B, driven by AMVUTTRA and TTR franchise growth.ALNY
Q2 2026 - Vutrisiran demonstrated robust mortality reduction and is poised for a major Q2 2025 launch.ALNY
2024 Wells Fargo Healthcare Conference - Cardiomyopathy launch fueled record growth and upgraded guidance, with robust pipeline momentum.ALNY
Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum